Citigroup Inc Aravive, Inc. Transaction History

Citigroup Inc

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	BUY	$1.2 - $1.83 $26,385 - $40,238	21,988 New	21,988 $29,000
Q2 2022 Aug 10, 2022	SELL	$0.93 - $1.9 $1,375 - $2,810	-1,479 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$1.85 - $2.75 $2,736 - $4,067	1,479 New	1,479 $3,000

28.1K

Ticker ARAV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,518,300
Description
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.